Clinical Trial Update: Safety of GX-188E DNA Therapeutic Vaccine Administered by Electroporation to Cervical Intraepithelial Neoplasia Grade 3 [Phase 1]

View source ↗

Summary

Phase 1 trial update reporting safety findings for GX-188E, a DNA therapeutic vaccine delivered by electroporation, in Cervical intraepithelial neoplasia grade …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Intraepithelial Neoplasia

Drugs mentioned

• GX-188E (GX-188E DNA vaccine)

Snippet

Sponsor: Genexine, Inc. | Conditions: Cervical Intraepithelial Neoplasia 3 | Phase 1 | Status: COMPLETED